G-Omeprazole 40 mg/vial (IV Injection)
40 mg vial: ৳ 75.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Omeprazole |
| Company | Gonoshasthaya pharma ltd |
| Also available as |
Indications
- Gastric and duodenal ulcer
- NSAID-associated duodenal and gastric ulcer
- As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
- Gastro-esophageal reflux disease
- Long-term management of acid reflux disease
- Acid-related dyspepsia
- Severe ulcerating reflux esophagitis
- Prophylaxis of acid aspiration during general anesthesia
- Zollinger-Ellison syndrome
- Helicobacter pylori-induced peptic ulcer
Pharmacology
- Substituted benzimidazole
- Inhibitor of gastric acid secretion
- Blocks hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
- Onset of antisecretory effect within one hour
- Maximum effect occurring within two hours
- Inhibition of secretion lasts up to 72 hours
- Secretory activity returns gradually over 3 to 5 days after discontinuation
Dosage
- Oral administration
- 20 mg once daily for benign gastric and duodenal ulcer for 4-8 weeks
- 40 mg daily for severe or recurrent cases
- 20 mg once daily for NSAID-associated duodenal or gastric ulcer
- 20 mg once daily for gastro-esophageal reflux disease for 4-8 weeks
- 40 mg once daily for refractory cases of gastro-esophageal reflux disease
- 10-20 mg daily for long-term management of acid reflux disease
- 10-20 mg once daily for acid-related dyspepsia for 2-4 weeks
Administration
- Oral administration
- Intravenous injection
- Intravenous infusion over 20-30 minutes or more
- Reconstitution of injection and infusion
- Slow intravenous injection over at least 2 to 5 minutes
- Use within specified time after reconstitution
Interaction
- Decreased intragastric acidity affecting absorption of ketoconazole
- Metabolism in the liver through cytochrome P450
- Potential delay in elimination of diazepam, phenytoin, and warfarin
- Possible increase in plasma concentrations of omeprazole and clarithromycin during concomitant administration
Contraindications
- Known hypersensitivity to omeprazole
- Suspected gastric ulcer with possibility of malignancy
Side Effects
- Skin rash, urticaria, and pruritus
- Photosensitivity, bullous eruption, and erythema multiforme
- Diarrhoea, headache, constipation, nausea/vomiting, and abdominal pain
- Dry mouth, stomatitis, and candidiasis
- Dizziness, somnolence, insomnia, and vertigo
- Reversible mental confusion, agitation, depression, and hallucinations
- Arthritic and myalgic symptoms
Pregnancy & Lactation
- No adverse effects on pregnancy or on the health of the fetus/newborn child based on epidemiological studies
- Usage during pregnancy possible
- No information available on passage into breast milk or its effects on the neonate
- Discontinuation of breastfeeding if essential use of omeprazole is considered
Precautions & Warnings
- Avoid concomitant use with clopidogrel
- Possible association with increased risk for osteoporosis-related fractures
- Atrophic gastritis noted occasionally in long-term treatment
- Potential for methotrexate toxicities with concomitant use of PPIs
Therapeutic Class
Proton Pump Inhibitor
Storage Conditions
Dry place away from light and heat, Keep out of the reach of children